[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Dasatinib.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dasatinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Dasatinib.]
[L04AA27, fingolimod, Dasatinib may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dasatinib.]
[M04AB02, sulfinpyrazone, Dasatinib may increase the anticoagulant activities of Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sulpiride.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dasatinib.]
[N06DA01, tacrine, The metabolism of Dasatinib can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The serum concentration of Dasatinib can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Dasatinib.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dasatinib.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Dasatinib can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Dasatinib can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Dasatinib.]
[N04BC07, apomorphine, The metabolism of Dasatinib can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dasatinib.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Dasatinib.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Dasatinib.]
[P02CA02, thiabendazole, The metabolism of Dasatinib can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Dasatinib.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Dasatinib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Thiothixene.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Dasatinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Dasatinib.]
[B01AC05, ticlopidine, Dasatinib may increase the anticoagulant activities of Ticlopidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Dasatinib.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Dasatinib.]
[C01DX11, trapidil, Dasatinib may increase the anticoagulant activities of Trapidil.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dasatinib.]
[L01XF01, tretinoin, The metabolism of Dasatinib can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Dasatinib can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The metabolism of Dasatinib can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The metabolism of Dasatinib can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Dasatinib.]
[N05AB06, trifluoperazine, The metabolism of Dasatinib can be decreased when combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Dasatinib.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Dasatinib can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dasatinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Dasatinib.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Dasatinib.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dasatinib.]
[J01FA08, troleandomycin, The metabolism of Dasatinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Dasatinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belimumab.]
[L01EX04, vandetanib, The serum concentration of Dasatinib can be increased when it is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Dasatinib can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Dasatinib can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Dasatinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Dasatinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Dasatinib can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Urokinase.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Dasatinib can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Dasatinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Dasatinib can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Dasatinib.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Dasatinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dasatinib.]
[A11HA03, vitamin E, The metabolism of Dasatinib can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Warfarin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Dasatinib.]
[N05AF05, zuclopenthixol, The metabolism of Dasatinib can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Dasatinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Dasatinib can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Dasatinib.]
[L01ED01, crizotinib, The metabolism of Dasatinib can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Dasatinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib.]
[J01MA13, trovafloxacin, The metabolism of Dasatinib can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Dasatinib can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.]
[N02BA01, aspirin, Dasatinib may increase the anticoagulant activities of Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Dasatinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Dasatinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dasatinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Dasatinib.]
[J02AC03, voriconazole, The metabolism of Dasatinib can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Atropine.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Dasatinib.]
[R07AX02, ivacaftor, The serum concentration of Dasatinib can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Dasatinib can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dasatinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Dasatinib.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Dasatinib.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dasatinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Dasatinib.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dasatinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Dasatinib.]
[G04BD12, mirabegron, The serum concentration of Dasatinib can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Dasatinib can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Dasatinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dasatinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Dasatinib.]
[L04AA31, teriflunomide, The serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Defibrotide.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Dasatinib is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Dasatinib can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Dasatinib can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Dasatinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Bendamustine.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Dasatinib.]
[C08CA13, lercanidipine, The metabolism of Dasatinib can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, Dasatinib may decrease the excretion rate of Donepezil which could result in a higher serum level.]
[N03AX22, perampanel, The metabolism of Dasatinib can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Dasatinib.]
[N02CC03, zolmitriptan, The metabolism of Dasatinib can be decreased when combined with Zolmitriptan.]
[H01CB05, pasireotide, The metabolism of Dasatinib can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Dasatinib can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Dasatinib can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Dasatinib.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bencyclane.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Dasatinib can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Dasatinib.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Dasatinib.]
[A10BK02, canagliflozin, The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The metabolism of Dasatinib can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Dasatinib can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Dasatinib can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Dasatinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Benzocaine.]
[M01AH01, celecoxib, Dasatinib may decrease the excretion rate of Celecoxib which could result in a higher serum level.]
[L04AA18, everolimus, The serum concentration of Dasatinib can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dasatinib.]
[L01EC02, dabrafenib, The serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dasatinib.]
[L01EB03, afatinib, The serum concentration of Dasatinib can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, Dasatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bepridil.]
[C02KX05, riociguat, Dasatinib may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Dasatinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Dasatinib.]
[N06AX26, vortioxetine, The metabolism of Dasatinib can be decreased when combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The metabolism of Dasatinib can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Dasatinib can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Dasatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Dasatinib can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Dasatinib can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Dasatinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dasatinib can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Dasatinib can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Dasatinib can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Dasatinib can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Argatroban.]
[L04AC11, siltuximab, The metabolism of Dasatinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Dasatinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dasatinib.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Dasatinib.]
[N07XX08, tafamidis, The serum concentration of Dasatinib can be increased when it is combined with Tafamidis.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Dasatinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Dasatinib can be increased when it is combined with Technetium Tc-99m sestamibi.]
[N03AG01, valproic acid, The metabolism of Dasatinib can be decreased when combined with Valproic acid.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Dasatinib can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The metabolism of Dasatinib can be decreased when combined with Pipemidic acid.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Dasatinib is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The serum concentration of Dasatinib can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Dasatinib.]
[J01XA05, oritavancin, The metabolism of Dasatinib can be increased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Dasatinib can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Dasatinib.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Dasatinib can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Dasatinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Dasatinib can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, Dasatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Dasatinib.]
[J05AP07, daclatasvir, The serum concentration of Dasatinib can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Dasatinib can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Dasatinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Dasatinib can be increased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Dasatinib.]
[A04AD14, rolapitant, The serum concentration of Dasatinib can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Dasatinib can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EC01, acetazolamide, The metabolism of Dasatinib can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dasatinib.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Dasatinib can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Dasatinib can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dasatinib.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Dasatinib.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Dasatinib.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Dasatinib.]
[B01AC27, selexipag, The serum concentration of Dasatinib can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Dasatinib.]
[M04AB05, lesinurad, The metabolism of Dasatinib can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Dasatinib can be decreased when combined with Elbasvir.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[N05CA05, aprobarbital, The metabolism of Dasatinib can be increased when combined with Aprobarbital.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Dasatinib can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Dasatinib.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dasatinib.]
[N05AX17, pimavanserin, The metabolism of Dasatinib can be decreased when combined with Pimavanserin.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Dasatinib.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Dasatinib can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Dasatinib can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Dasatinib.]
[L01XX27, arsenic trioxide, The serum concentration of Dasatinib can be increased when it is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Dasatinib can be decreased when combined with Artemether.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dasatinib.]
[S01GX07, azelastine, The metabolism of Dasatinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Dasatinib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Dasatinib can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Dasatinib can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Dasatinib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Dasatinib can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dasatinib.]
[N06BC01, caffeine, The metabolism of Dasatinib can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Dasatinib can be increased when combined with Calcitriol.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Dasatinib.]
[J05AE09, tipranavir, The metabolism of Dasatinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Dasatinib.]
[N07XX13, valbenazine, The metabolism of Dasatinib can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Dasatinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dasatinib can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Dasatinib.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Dasatinib.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AC14, sarilumab, The metabolism of Dasatinib can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Dasatinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Dasatinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Dasatinib.]
[L01XX59, enasidenib, The serum concentration of Dasatinib can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Dasatinib can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dasatinib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Dasatinib is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Dasatinib.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Dasatinib.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Dasatinib can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Dasatinib can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Dasatinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dasatinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Dasatinib.]
[R03BA02, budesonide, The metabolism of Dasatinib can be increased when combined with Budesonide.]
[C04AX20, buflomedil, Dasatinib may increase the anticoagulant activities of Buflomedil.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Dasatinib.]
[J05AX18, letermovir, The metabolism of Dasatinib can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, Dasatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Dasatinib can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dasatinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Dasatinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dasatinib.]
[C07AG02, carvedilol, The serum concentration of Dasatinib can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Dasatinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Dasatinib can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Baricitinib.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Dasatinib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Dasatinib can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Dasatinib can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Dasatinib can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Dasatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Dasatinib can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Dasatinib can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Dasatinib can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Dasatinib can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Dasatinib can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Dasatinib can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dasatinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Chloroprocaine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Dasatinib.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Inotersen.]
[L01XK04, talazoparib, Dasatinib may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[R03BB08, revefenacin, Dasatinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The serum concentration of Dasatinib can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Dasatinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Dasatinib.]
[L01EX12, larotrectinib, The serum concentration of Dasatinib can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Dasatinib can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Dasatinib can be increased when it is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Dasatinib.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Cibenzoline.]
[B01AX07, caplacizumab, Dasatinib may increase the anticoagulant activities of Caplacizumab.]
[B01AC23, cilostazol, Dasatinib may increase the anticoagulant activities of Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Dasatinib can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Dasatinib can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Dasatinib.]
[J01FA09, clarithromycin, The metabolism of Dasatinib can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Dasatinib can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Dasatinib can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Dasatinib can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Dasatinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Dasatinib can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Dasatinib.]
[L02BB06, darolutamide, The serum concentration of Dasatinib can be increased when it is combined with Darolutamide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Dasatinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The metabolism of Dasatinib can be decreased when combined with Cyclobenzaprine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Dasatinib can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Dasatinib can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Dasatinib can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Dasatinib.]
[N04CX01, istradefylline, The serum concentration of Dasatinib can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Dasatinib.]
[A10AE03, insulin, regular, pork, The metabolism of Dasatinib can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Dasatinib can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The metabolism of Dasatinib can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Dasatinib can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Dasatinib can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Dasatinib.]
[N02CC08, lasmiditan, The serum concentration of Dasatinib can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Dasatinib.]
[B06AX03, voxelotor, The serum concentration of Dasatinib can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Dasatinib can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Dasatinib can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Dasatinib.]
[L01FX13, enfortumab vedotin, The serum concentration of Dasatinib can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dasatinib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The metabolism of Dasatinib can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Dasatinib can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Dasatinib can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Dasatinib.]
[J05AB16, remdesivir, The metabolism of Dasatinib can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The metabolism of Dasatinib can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Dasatinib can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dasatinib can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Dasatinib can be decreased when combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dasatinib can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Dasatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The metabolism of Dasatinib can be decreased when combined with Selumetinib.]
[M01AH02, rofecoxib, The metabolism of Dasatinib can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Dasatinib can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Dasatinib can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Dasatinib can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Dasatinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dasatinib.]
[S03AA08, chloramphenicol, The metabolism of Dasatinib can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Chlorcyclizine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Dasatinib can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Dasatinib can be increased when combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Dasatinib can be increased when it is combined with Ripretinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Dasatinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Dasatinib.]
[R06AX22, ebastine, The metabolism of Dasatinib can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, Dasatinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Dasatinib can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Dasatinib can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Dasatinib can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Dasatinib.]
[R06AB04, chlorpheniramine, The metabolism of Dasatinib can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Dasatinib can be increased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dasatinib.]
[M03BB03, chlorzoxazone, The metabolism of Dasatinib can be decreased when combined with Chlorzoxazone.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Dasatinib.]
[A16AX20, lonafarnib, The metabolism of Dasatinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Dasatinib.]
[L02BX04, relugolix, The metabolism of Dasatinib can be decreased when combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Dasatinib can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Dasatinib can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Dasatinib can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Dasatinib can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The metabolism of Dasatinib can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Dasatinib can be increased when combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Dasatinib.]
[G04CB01, finasteride, The metabolism of Dasatinib can be decreased when combined with Finasteride.]
[J01MB07, flumequine, The metabolism of Dasatinib can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The metabolism of Dasatinib can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Dasatinib can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dasatinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Dasatinib.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Dasatinib can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07CA02, cinnarizine, The metabolism of Dasatinib can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Dasatinib can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Dasatinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Dasatinib can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Dasatinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib.]
[N06AB04, citalopram, The metabolism of Dasatinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Dasatinib can be increased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Dasatinib.]
[L04AA48, belumosudil, The serum concentration of Dasatinib can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Dasatinib is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Dasatinib can be decreased when it is combined with Belzutifan.]
[H01AC09, lonapegsomatropin, The metabolism of Dasatinib can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Dasatinib can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Dasatinib can be decreased when combined with Mefenamic acid.]
[J01FF01, clindamycin, The metabolism of Dasatinib can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Dasatinib can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Dasatinib can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Dasatinib can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The serum concentration of Dasatinib can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Dasatinib can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Dasatinib can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Dasatinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Dasatinib can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Dasatinib can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Dasatinib.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Dasatinib.]
[C01EB24, mavacamten, The serum concentration of Dasatinib can be decreased when it is combined with Mavacamten.]
[J02AC06, oteseconazole, The serum concentration of Dasatinib can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, Vonoprazan can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Dasatinib can be decreased when combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Dasatinib can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The serum concentration of Dasatinib can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Dasatinib is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Dasatinib can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Dasatinib can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Dasatinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Dasatinib can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Dasatinib.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dasatinib.]
[A10BX03, nateglinide, The metabolism of Dasatinib can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Dasatinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ciclesonide.]
[B01AC10, indobufen, Dasatinib may increase the anticoagulant activities of Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Desloratadine.]
[J02AC02, itraconazole, The metabolism of Dasatinib can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Dasatinib can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Dasatinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Dasatinib can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Dasatinib can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dasatinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Dasatinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dasatinib.]
[S01BA03, cortisone, The metabolism of Dasatinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Dasatinib.]
[S01AE04, lomefloxacin, The metabolism of Dasatinib can be decreased when combined with Lomefloxacin.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Dasatinib can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Dasatinib can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Dasatinib can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Dasatinib.]
[C03DA04, eplerenone, The metabolism of Dasatinib can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Dasatinib.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Dasatinib.]
[J01FA03, midecamycin, The metabolism of Dasatinib can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Dasatinib can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Dasatinib can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Dasatinib may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Dasatinib can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dasatinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dasatinib.]
[C10AA07, rosuvastatin, The metabolism of Dasatinib can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Dasatinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dasatinib.]
[J05AF10, entecavir, The metabolism of Dasatinib can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Dasatinib.]
[M01AH05, etoricoxib, The metabolism of Dasatinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dasatinib.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dasatinib.]
[G03XA01, danazol, The metabolism of Dasatinib can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dasatinib can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Dasatinib can be decreased when combined with Daunorubicin.]
[M01AX01, nabumetone, The metabolism of Dasatinib can be decreased when combined with Nabumetone.]
[N06AX06, nefazodone, The metabolism of Dasatinib can be decreased when combined with Nefazodone.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Dasatinib.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fondaparinux.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Solifenacin.]
[N06AA01, desipramine, The metabolism of Dasatinib can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Dasatinib.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dasatinib.]
[N03AF02, oxcarbazepine, The metabolism of Dasatinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dasatinib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Dasatinib can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dasatinib can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Dasatinib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Dasatinib can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Dasatinib can be decreased when combined with Dextromethorphan.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Dasatinib.]
[N06AB05, paroxetine, The metabolism of Dasatinib can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, Dasatinib may increase the anticoagulant activities of Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Dasatinib.]
[N05BA01, diazepam, The metabolism of Dasatinib can be decreased when combined with Diazepam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Dasatinib can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Dasatinib can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dasatinib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Pinaverium.]
[L01DC04, ixabepilone, The serum concentration of Dasatinib can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Dasatinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Dasatinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Dasatinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Dasatinib can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Dasatinib.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dasatinib.]
[C02DB01, dihydralazine, The metabolism of Dasatinib can be decreased when combined with Dihydralazine.]
[C10AX09, ezetimibe, Dasatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dasatinib.]
[C04AE04, dihydroergocristine, The metabolism of Dasatinib can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Dasatinib.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dasatinib.]
[J05AE08, atazanavir, The metabolism of Dasatinib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dasatinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Dasatinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Dasatinib can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Dasatinib can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Dasatinib.]
[C05CA03, diosmin, The serum concentration of Dasatinib can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Dasatinib.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Dasatinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Dasatinib.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Dasatinib can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Dasatinib can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dasatinib can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Dasatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Dasatinib can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levocetirizine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Dasatinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Dasatinib can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Dasatinib.]
[A04AD12, aprepitant, The metabolism of Dasatinib can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Dasatinib.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Dasatinib.]
[J05AE07, fosamprenavir, The metabolism of Dasatinib can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Dasatinib can be decreased when combined with Tadalafil.]
[C02KX02, ambrisentan, The metabolism of Dasatinib can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Dasatinib can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Dasatinib can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dasatinib.]
[A03FA03, domperidone, The metabolism of Dasatinib can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dasatinib can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Doxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Dasatinib.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dasatinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Dasatinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Droperidol.]
[C10AA01, simvastatin, The serum concentration of Dasatinib can be increased when it is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sultopride.]
[N02CC01, sumatriptan, Dasatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Talinolol.]
[H01AA01, corticotropin, The metabolism of Dasatinib can be increased when combined with Corticotropin.]
[J01MA05, temafloxacin, The metabolism of Dasatinib can be decreased when combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Dasatinib.]
[D01BA02, terbinafine, The metabolism of Dasatinib can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Terodiline.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Dasatinib.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dasatinib.]
[N03AX11, topiramate, The metabolism of Dasatinib can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Dasatinib can be increased when it is combined with Toremifene.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Dasatinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Troxerutin.]
[J01MA04, enoxacin, The metabolism of Dasatinib can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Dasatinib.]
[S01GX10, epinastine, Epinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Dasatinib which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Dasatinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Dasatinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Dasatinib.]
[N05CF02, zolpidem, The metabolism of Dasatinib can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The serum concentration of Dasatinib can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Dasatinib.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Dasatinib.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dasatinib.]
[B01AC11, iloprost, Dasatinib may increase the anticoagulant activities of Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Dasatinib.]
[N02CA02, ergotamine, The metabolism of Dasatinib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Dasatinib can be increased when it is combined with Erythromycin.]
[A02BC02, pantoprazole, Pantoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H05BX01, cinacalcet, The metabolism of Dasatinib can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Dasatinib can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Dasatinib.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Dasatinib can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Dasatinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Dasatinib can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Dasatinib can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Dasatinib can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Dasatinib can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Dasatinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Dasatinib.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Dasatinib.]
[R06AX12, terfenadine, The metabolism of Dasatinib can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Dasatinib can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Dasatinib can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Dasatinib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Dasatinib.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dextran.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dasatinib.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P02CA03, albendazole, The metabolism of Dasatinib can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Dasatinib can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Dasatinib can be decreased when combined with Fenfluramine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Dasatinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dasatinib.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Dasatinib.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Dasatinib.]
[C01BC04, flecainide, The metabolism of Dasatinib can be decreased when combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Dasatinib can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Dasatinib can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Dasatinib.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dasatinib.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Dasatinib.]
[D07AC08, fluocinonide, The metabolism of Dasatinib can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Dasatinib can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Dasatinib can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Dasatinib.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dasatinib.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dasatinib.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dasatinib.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dasatinib.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Dasatinib can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Dasatinib may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Dasatinib.]
[J05AE10, darunavir, The serum concentration of Dasatinib can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Dasatinib.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dasatinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Dasatinib can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Dasatinib can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Degarelix.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Dasatinib.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Dasatinib.]
[J05AG04, etravirine, The metabolism of Dasatinib can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methsuximide.]
[N01AH02, alfentanil, The metabolism of Dasatinib can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Dasatinib can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Dasatinib can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The metabolism of Dasatinib can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Dasatinib.]
[C02CA04, doxazosin, The metabolism of Dasatinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dasatinib.]
[L01EX02, sorafenib, The serum concentration of Dasatinib can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dasatinib.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fluindione.]
[D01BA01, griseofulvin, The metabolism of Dasatinib can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Dasatinib can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Histrelin.]
[N05AH04, quetiapine, The metabolism of Dasatinib can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Dasatinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Dasatinib.]
[C09CA01, losartan, The metabolism of Dasatinib can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Dasatinib can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Dasatinib.]
[J05AG01, nevirapine, The metabolism of Dasatinib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Dasatinib can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Dasatinib may increase the anticoagulant activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Oxatomide.]
[C02DB02, hydralazine, The metabolism of Dasatinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dasatinib.]
[S02BA01, hydrocortisone, The metabolism of Dasatinib can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Dasatinib.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dasatinib.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Dasatinib can be increased when combined with Rifabutin.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Dasatinib.]
[L01AA06, ifosfamide, The metabolism of Dasatinib can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, The metabolism of Dasatinib can be increased when combined with Somatrem.]
[N06AA02, imipramine, The metabolism of Dasatinib can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Dasatinib can be increased when combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Dasatinib is combined with Tixocortol.]
[M03BX02, tizanidine, The metabolism of Dasatinib can be decreased when combined with Tizanidine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Dasatinib.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dasatinib.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dasatinib.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dasatinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dasatinib.]
[N06AX17, milnacipran, The metabolism of Dasatinib can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Dasatinib can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Dasatinib.]
[N05CH02, ramelteon, The metabolism of Dasatinib can be decreased when combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dasatinib.]
[C10AA06, cerivastatin, The metabolism of Dasatinib can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, Dasatinib may increase the anticoagulant activities of Anagrelide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dasatinib.]
[J05AB13, penciclovir, The metabolism of Dasatinib can be decreased when combined with Penciclovir.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Dasatinib.]
[J04AC01, isoniazid, The metabolism of Dasatinib can be decreased when combined with Isoniazid.]
[P02CF01, ivermectin, Dasatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bivalirudin.]
[H01AC01, somatropin, The metabolism of Dasatinib can be increased when combined with Somatotropin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Dasatinib can be increased when combined with Tocilizumab.]
[C02KD01, ketanserin, Dasatinib may increase the anticoagulant activities of Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Dasatinib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Dasatinib can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AC03, deferasirox, The serum concentration of Dasatinib can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Dasatinib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mizolastine.]
[J01MB02, nalidixic acid, The metabolism of Dasatinib can be decreased when combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dasatinib.]
[N03AX18, lacosamide, The metabolism of Dasatinib can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Dasatinib.]
[G03AD01, levonorgestrel, The metabolism of Dasatinib can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Dasatinib can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Dasatinib.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Dasatinib.]
[A07DA03, loperamide, The serum concentration of Dasatinib can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Dasatinib.]
[N05AH01, loxapine, The serum concentration of Dasatinib can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Dasatinib can be increased when it is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Dasatinib can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Dasatinib can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dasatinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dasatinib.]
[P01BC02, mefloquine, The serum concentration of Dasatinib can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Dasatinib can be decreased when combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Dasatinib.]
[N02AB02, meperidine, The metabolism of Dasatinib can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Dasatinib can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Dasatinib can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Dasatinib can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mesoridazine.]
[N05AX13, paliperidone, The serum concentration of Dasatinib can be increased when it is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Dasatinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Dasatinib can be decreased when combined with Methadone.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF05, lamivudine, Dasatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[H03BB02, methimazole, The metabolism of Dasatinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dasatinib.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Dasatinib.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Dasatinib can be decreased when combined with Methoxsalen.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dasatinib.]
[V04CG05, methylene blue, The serum concentration of Dasatinib can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Dasatinib can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Dasatinib.]
[H02AB04, methylprednisolone, The metabolism of Dasatinib can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Dasatinib can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Dasatinib can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dasatinib.]
[P01AB01, metronidazole, The metabolism of Dasatinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Dasatinib can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Dasatinib can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Dasatinib.]
[S02AA13, miconazole, The metabolism of Dasatinib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Dasatinib.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Dasatinib.]
[G03XB01, mifepristone, The serum concentration of Dasatinib can be decreased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tinzaparin.]
[J01FA11, miocamycin, The metabolism of Dasatinib can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Dasatinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dasatinib.]
[L03AC01, aldesleukin, The metabolism of Dasatinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Dasatinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Dasatinib can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Dasatinib can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Dasatinib can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Dasatinib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dasatinib.]
[N05CA02, amobarbital, The metabolism of Dasatinib can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dasatinib.]
[G04CA04, silodosin, The serum concentration of Dasatinib can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Dasatinib can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dasatinib.]
[N03AB05, fosphenytoin, The metabolism of Dasatinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dasatinib.]
[J01CF06, nafcillin, The metabolism of Dasatinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Dasatinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Dasatinib can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Dasatinib can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Dasatinib can be increased when combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dasatinib.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Dasatinib.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levosimendan.]
[B01AC17, tirofiban, Dasatinib may increase the anticoagulant activities of Tirofiban.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Dasatinib.]
[N06AX23, desvenlafaxine, The metabolism of Dasatinib can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Dasatinib can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Dasatinib.]
[C10AD02, niacin, The metabolism of Dasatinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Dasatinib can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Dasatinib can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Dasatinib can be decreased when combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Nimodipine.]
[C08CA07, nisoldipine, The metabolism of Dasatinib can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Dasatinib can be decreased when combined with Nitrendipine.]
[J01XE01, nitrofurantoin, Dasatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Dasatinib can be decreased when combined with Zaleplon.]
[G03DC02, norethindrone, The metabolism of Dasatinib can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The metabolism of Dasatinib can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Dasatinib can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Dasatinib.]
[R05DA07, noscapine, The metabolism of Dasatinib can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Dasatinib can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, Dasatinib may increase the anticoagulant activities of Eptifibatide.]
[L03AB07, interferon beta-1a, The metabolism of Dasatinib can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Dasatinib can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Dasatinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Dasatinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ancrod.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Oxolinic acid.]
[N02AA05, oxycodone, The metabolism of Dasatinib can be decreased when combined with Oxycodone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.]
[N05AH05, asenapine, Asenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Danaparoid.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Papaverine.]
[H02AB05, paramethasone, The metabolism of Dasatinib can be increased when combined with Paramethasone.]
[J01MA03, pefloxacin, The metabolism of Dasatinib can be decreased when combined with Pefloxacin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Dasatinib.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dasatinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dasatinib.]
[N05CA01, pentobarbital, The metabolism of Dasatinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Dasatinib.]
[C04AD03, pentoxifylline, Dasatinib may increase the anticoagulant activities of Pentoxifylline.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Dasatinib.]
[N05AB03, perphenazine, The metabolism of Dasatinib can be decreased when combined with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dasatinib.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Dasatinib.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Dasatinib can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The metabolism of Dasatinib can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Dasatinib can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB02, phenytoin, The metabolism of Dasatinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dasatinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Dasatinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The serum concentration of Dasatinib can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Dasatinib.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Dasatinib.]
[J05AE01, saquinavir, The metabolism of Dasatinib can be decreased when combined with Saquinavir.]
[J01MA11, grepafloxacin, The metabolism of Dasatinib can be decreased when combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Dasatinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Dasatinib can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Alteplase.]
[A03AE01, alosetron, The metabolism of Dasatinib can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Dasatinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Dasatinib.]
[J05AE03, ritonavir, The metabolism of Dasatinib can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Dasatinib can be decreased when combined with Saxagliptin.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Dasatinib.]
[C10AA08, pitavastatin, Dasatinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Dasatinib can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Dasatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The metabolism of Dasatinib can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Dasatinib.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Dasatinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dasatinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Dasatinib can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Dasatinib.]
[C10AB05, fenofibrate, The metabolism of Dasatinib can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Dasatinib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Dasatinib can be decreased when combined with Promazine.]
[R06AD02, promethazine, Promethazine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01BC03, propafenone, The serum concentration of Dasatinib can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Dasatinib can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Dasatinib.]
[N01AX10, propofol, The metabolism of Dasatinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dasatinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Dasatinib can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dasatinib.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dasatinib.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Dasatinib.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dasatinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Dasatinib can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Dasatinib can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Dasatinib can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02AA02, reserpine, The serum concentration of Dasatinib can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Dasatinib can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Dasatinib can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dasatinib.]
[N05CA06, secobarbital, The metabolism of Dasatinib can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Dasatinib can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.]
[H01CB01, somatostatin, The metabolism of Dasatinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Dasatinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.]
[D07AB02, hydrocortisone butyrate, The metabolism of Dasatinib can be increased when combined with Hydrocortisone butyrate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Dasatinib.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Streptokinase.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dasatinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Dasatinib.]
[L04AA27, fingolimod, Dasatinib may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dasatinib.]
[M04AB02, sulfinpyrazone, Dasatinib may increase the anticoagulant activities of Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sulpiride.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Dasatinib.]
[N06DA01, tacrine, The metabolism of Dasatinib can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The serum concentration of Dasatinib can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Dasatinib.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dasatinib.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Dasatinib can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Dasatinib can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Dasatinib.]
[N04BC07, apomorphine, The metabolism of Dasatinib can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dasatinib.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Dasatinib.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Dasatinib.]
[P02CA02, thiabendazole, The metabolism of Dasatinib can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Eribulin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Dasatinib.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Dasatinib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Thiothixene.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Dasatinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Dasatinib.]
[B01AC05, ticlopidine, Dasatinib may increase the anticoagulant activities of Ticlopidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Dasatinib.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Dasatinib.]
[C01DX11, trapidil, Dasatinib may increase the anticoagulant activities of Trapidil.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Dasatinib.]
[L01XF01, tretinoin, The metabolism of Dasatinib can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Dasatinib can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The metabolism of Dasatinib can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The metabolism of Dasatinib can be decreased when combined with Triazolam.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Dasatinib.]
[N05AB06, trifluoperazine, The metabolism of Dasatinib can be decreased when combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Dasatinib.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Fluclorolone.]
[R03BA07, mometasone, The metabolism of Dasatinib can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Dasatinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Dasatinib.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Dasatinib.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Dasatinib.]
[J01FA08, troleandomycin, The metabolism of Dasatinib can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Dasatinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belimumab.]
[L01EX04, vandetanib, The serum concentration of Dasatinib can be increased when it is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Dasatinib can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Dasatinib can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Dasatinib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Dasatinib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Dasatinib can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Urokinase.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ezogabine.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Dasatinib can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Dasatinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Dasatinib can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Dasatinib.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Dasatinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dasatinib.]
[A11HA03, vitamin E, The metabolism of Dasatinib can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Dasatinib can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Dasatinib.]
[N05AF05, zuclopenthixol, The metabolism of Dasatinib can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Dasatinib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Dasatinib can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Dasatinib.]
[L01ED01, crizotinib, The metabolism of Dasatinib can be decreased when combined with Crizotinib.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Dasatinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib.]
[J01MA13, trovafloxacin, The metabolism of Dasatinib can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Dasatinib can be decreased when combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dasatinib.]
[N02BA01, aspirin, Dasatinib may increase the anticoagulant activities of Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Dasatinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Dasatinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dasatinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Dasatinib.]
[J02AC03, voriconazole, The metabolism of Dasatinib can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Atropine.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Dasatinib.]
[R07AX02, ivacaftor, The serum concentration of Dasatinib can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Dasatinib can be increased when combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dasatinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Dasatinib.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Dasatinib.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dasatinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Dasatinib.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dasatinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dasatinib.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Dasatinib.]
[G04BD12, mirabegron, The serum concentration of Dasatinib can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Dasatinib can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Dasatinib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dasatinib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Dasatinib.]
[L04AA31, teriflunomide, The serum concentration of Dasatinib can be decreased when it is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Defibrotide.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Dasatinib is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Dasatinib can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Dasatinib can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Dasatinib can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Bendamustine.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Dasatinib.]
[C08CA13, lercanidipine, The metabolism of Dasatinib can be decreased when combined with Lercanidipine.]
[N06DA02, donepezil, Dasatinib may decrease the excretion rate of Donepezil which could result in a higher serum level.]
[N03AX22, perampanel, The metabolism of Dasatinib can be increased when combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Dasatinib.]
[N02CC03, zolmitriptan, The metabolism of Dasatinib can be decreased when combined with Zolmitriptan.]
[H01CB05, pasireotide, The metabolism of Dasatinib can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Dasatinib can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Dasatinib can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Dasatinib.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bencyclane.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Dasatinib can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Dasatinib.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Dasatinib.]
[A10BK02, canagliflozin, The serum concentration of Dasatinib can be increased when it is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The metabolism of Dasatinib can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Dasatinib can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Dasatinib can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Dasatinib.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Benzocaine.]
[M01AH01, celecoxib, Dasatinib may decrease the excretion rate of Celecoxib which could result in a higher serum level.]
[L04AA18, everolimus, The serum concentration of Dasatinib can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dasatinib.]
[L01EC02, dabrafenib, The serum concentration of Dasatinib can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Benzyl alcohol.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dasatinib.]
[L01EB03, afatinib, The serum concentration of Dasatinib can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, Dasatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bepridil.]
[C02KX05, riociguat, Dasatinib may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Dasatinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Dasatinib.]
[N06AX26, vortioxetine, The metabolism of Dasatinib can be decreased when combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The metabolism of Dasatinib can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Dasatinib can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Dasatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The metabolism of Dasatinib can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The metabolism of Dasatinib can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Dasatinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dasatinib can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Dasatinib can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Dasatinib can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Dasatinib can be decreased when combined with Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Argatroban.]
[L04AC11, siltuximab, The metabolism of Dasatinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Dasatinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Dasatinib.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Dasatinib is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Dasatinib.]
[N07XX08, tafamidis, The serum concentration of Dasatinib can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Dasatinib is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The serum concentration of Dasatinib can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Dasatinib.]
[J01XA05, oritavancin, The metabolism of Dasatinib can be increased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Dasatinib can be decreased when combined with Nintedanib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Blinatumomab.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Dasatinib.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Dasatinib can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Dasatinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Dasatinib can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, Dasatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Dasatinib.]
[J05AP07, daclatasvir, The serum concentration of Dasatinib can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Dasatinib can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Dasatinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Dasatinib can be increased when it is combined with Asunaprevir.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Cangrelor.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Dasatinib.]
[A04AD14, rolapitant, The serum concentration of Dasatinib can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Dasatinib can be increased when it is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EC01, acetazolamide, The metabolism of Dasatinib can be decreased when combined with Acetazolamide.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dasatinib.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Mepolizumab.]
[J02AC05, isavuconazole, The serum concentration of Dasatinib can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Dasatinib can be decreased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Dasatinib.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Dasatinib.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Dasatinib.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Dasatinib.]
[B01AC27, selexipag, The serum concentration of Dasatinib can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Dasatinib.]
[M04AB05, lesinurad, The metabolism of Dasatinib can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The metabolism of Dasatinib can be decreased when combined with Elbasvir.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[N05CA05, aprobarbital, The metabolism of Dasatinib can be increased when combined with Aprobarbital.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Dasatinib can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Dasatinib.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dasatinib.]
[N05AX17, pimavanserin, The metabolism of Dasatinib can be decreased when combined with Pimavanserin.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Dasatinib.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Dasatinib can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Dasatinib can be decreased when combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Dasatinib.]
[L01XX27, arsenic trioxide, The serum concentration of Dasatinib can be increased when it is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Dasatinib can be decreased when combined with Artemether.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dasatinib.]
[S01GX07, azelastine, The metabolism of Dasatinib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Dasatinib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Dasatinib can be decreased when combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Dasatinib can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Dasatinib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The metabolism of Dasatinib can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Dasatinib.]
[N06BC01, caffeine, The metabolism of Dasatinib can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Dasatinib can be increased when combined with Calcitriol.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Dasatinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Dasatinib.]
[J05AE09, tipranavir, The metabolism of Dasatinib can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Dasatinib.]
[N07XX13, valbenazine, The metabolism of Dasatinib can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Dasatinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dasatinib can be decreased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Dasatinib.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Dasatinib.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AC14, sarilumab, The metabolism of Dasatinib can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, Dasatinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[B01AF04, betrixaban, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Betrixaban.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Guselkumab.]
[D01AC10, bifonazole, The metabolism of Dasatinib can be decreased when combined with Bifonazole.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Dasatinib.]
[L01XX59, enasidenib, The serum concentration of Dasatinib can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Dasatinib can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dasatinib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Dasatinib is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Dasatinib.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Dasatinib.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Dasatinib can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Dasatinib can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Dasatinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dasatinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Dasatinib.]
[R03BA02, budesonide, The metabolism of Dasatinib can be increased when combined with Budesonide.]
[C04AX20, buflomedil, Dasatinib may increase the anticoagulant activities of Buflomedil.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Dasatinib.]
[J05AX18, letermovir, The metabolism of Dasatinib can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, Dasatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Dasatinib can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dasatinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Dasatinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dasatinib.]
[C07AG02, carvedilol, The serum concentration of Dasatinib can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Dasatinib can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Dasatinib can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Baricitinib.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Dasatinib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Celiprolol.]
[H01CC03, elagolix, The serum concentration of Dasatinib can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Dasatinib can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Dasatinib can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, Dasatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Dasatinib can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Dasatinib can be decreased when combined with Doravirine.]
[L01EM04, duvelisib, The metabolism of Dasatinib can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Dasatinib can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Dasatinib can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Dasatinib can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Dasatinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Chloroprocaine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Dasatinib.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Inotersen.]
[L01XK04, talazoparib, Dasatinib may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[R03BB08, revefenacin, Dasatinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The serum concentration of Dasatinib can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Dasatinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Dasatinib.]
[L01EX12, larotrectinib, The serum concentration of Dasatinib can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Dasatinib can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Dasatinib can be increased when it is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Amifampridine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Dasatinib.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Cibenzoline.]
[B01AX07, caplacizumab, Dasatinib may increase the anticoagulant activities of Caplacizumab.]
[B01AC23, cilostazol, Dasatinib may increase the anticoagulant activities of Cilostazol.]
[P02BX04, triclabendazole, The metabolism of Dasatinib can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Dasatinib can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Dasatinib.]
[J01FA09, clarithromycin, The metabolism of Dasatinib can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Dasatinib can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Dasatinib can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Dasatinib can be increased when combined with Cloprednol.]
[L04AB01, etanercept, The metabolism of Dasatinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Dasatinib can be increased when combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Dasatinib.]
[L02BB06, darolutamide, The serum concentration of Dasatinib can be increased when it is combined with Darolutamide.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Dasatinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The metabolism of Dasatinib can be decreased when combined with Cyclobenzaprine.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Dasatinib can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Dasatinib can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Dasatinib can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Dasatinib.]
[N04CX01, istradefylline, The serum concentration of Dasatinib can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Dasatinib.]
[A10AE03, insulin, regular, pork, The metabolism of Dasatinib can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The serum concentration of Dasatinib can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The metabolism of Dasatinib can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Dasatinib can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Dasatinib can be increased when combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Dasatinib.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Dasatinib.]
[N02CC08, lasmiditan, The serum concentration of Dasatinib can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Dasatinib.]
[B06AX03, voxelotor, The serum concentration of Dasatinib can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Dasatinib can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Dasatinib can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Dasatinib.]
[L01FX13, enfortumab vedotin, The serum concentration of Dasatinib can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dasatinib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dexchlorpheniramine.]
[N05CM21, lemborexant, The metabolism of Dasatinib can be decreased when combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Dasatinib can be decreased when combined with Tazemetostat.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Dasatinib can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Dasatinib.]
[J05AB16, remdesivir, The metabolism of Dasatinib can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The metabolism of Dasatinib can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The serum concentration of Dasatinib can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dasatinib can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Dasatinib can be decreased when combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dasatinib can be decreased when combined with Dutasteride.]
[L04AA38, ozanimod, Dasatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The metabolism of Dasatinib can be decreased when combined with Selumetinib.]
[M01AH02, rofecoxib, The metabolism of Dasatinib can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Dasatinib can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Dasatinib can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Dasatinib can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Dasatinib can be decreased when combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dasatinib.]
[S03AA08, chloramphenicol, The metabolism of Dasatinib can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Chlorcyclizine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Dasatinib can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The metabolism of Dasatinib can be increased when combined with Fluprednidene.]
[L01EX19, ripretinib, The serum concentration of Dasatinib can be increased when it is combined with Ripretinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Dasatinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Dasatinib.]
[R06AX22, ebastine, The metabolism of Dasatinib can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, Dasatinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level.]
[L01FX15, belantamab mafodotin, The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Dasatinib can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Dasatinib can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Dasatinib can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Dasatinib.]
[R06AB04, chlorpheniramine, The metabolism of Dasatinib can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Dasatinib can be increased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Dasatinib.]
[M03BB03, chlorzoxazone, The metabolism of Dasatinib can be decreased when combined with Chlorzoxazone.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Dasatinib.]
[A16AX20, lonafarnib, The metabolism of Dasatinib can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Dasatinib.]
[L02BX04, relugolix, The metabolism of Dasatinib can be decreased when combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Dasatinib can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Dasatinib can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Dasatinib can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Dasatinib can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The metabolism of Dasatinib can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Dasatinib can be increased when combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Dasatinib.]
[G04CB01, finasteride, The metabolism of Dasatinib can be decreased when combined with Finasteride.]
[J01MB07, flumequine, The metabolism of Dasatinib can be decreased when combined with Flumequine.]
[R03BA03, flunisolide, The metabolism of Dasatinib can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Dasatinib can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dasatinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Dasatinib.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Dasatinib can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07CA02, cinnarizine, The metabolism of Dasatinib can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Dasatinib can be decreased when combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Dasatinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Dasatinib can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Dasatinib can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib.]
[N06AB04, citalopram, The metabolism of Dasatinib can be decreased when combined with Citalopram.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Dasatinib can be increased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Dasatinib.]
[L04AA48, belumosudil, The serum concentration of Dasatinib can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Dasatinib is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Dasatinib can be decreased when it is combined with Belzutifan.]
[H01AC09, lonapegsomatropin, The metabolism of Dasatinib can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mobocertinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Dasatinib can be increased when it is combined with Technetium Tc-99m sestamibi.]
[L04AA59, avacopan, The metabolism of Dasatinib can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Clemastine.]
[J01FF01, clindamycin, The metabolism of Dasatinib can be decreased when combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Dasatinib can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Dasatinib can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Dasatinib can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The serum concentration of Dasatinib can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Dasatinib can be increased when it is combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Dasatinib can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Dasatinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Dasatinib can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Dasatinib can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Dasatinib.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Dasatinib.]
[C01EB24, mavacamten, The serum concentration of Dasatinib can be decreased when it is combined with Mavacamten.]
[J02AC06, oteseconazole, The serum concentration of Dasatinib can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, Vonoprazan can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Dasatinib is combined with Deucravacitinib.]
[A04AA01, ondansetron, The metabolism of Dasatinib can be decreased when combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Dasatinib can be decreased when combined with Lenacapavir.]
[L01XX77, adagrasib, The serum concentration of Dasatinib can be increased when it is combined with Adagrasib.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Dasatinib is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Dasatinib can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Dasatinib can be increased when it is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Dasatinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Dasatinib can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Dasatinib.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Leflunomide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dasatinib.]
[A10BX03, nateglinide, The metabolism of Dasatinib can be decreased when combined with Nateglinide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Dasatinib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ciclesonide.]
[B01AC10, indobufen, Dasatinib may increase the anticoagulant activities of Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Desloratadine.]
[J02AC02, itraconazole, The metabolism of Dasatinib can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bemiparin.]
[S01AD03, acyclovir, The metabolism of Dasatinib can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Dasatinib can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Dasatinib can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Dasatinib can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lacidipine.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dasatinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Dasatinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Dasatinib.]
[S01BA03, cortisone, The metabolism of Dasatinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The metabolism of Lofexidine can be decreased when combined with Dasatinib.]
[S01AE04, lomefloxacin, The metabolism of Dasatinib can be decreased when combined with Lomefloxacin.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Dasatinib can be decreased when combined with Manidipine.]
[H02AB15, meprednisone, The metabolism of Dasatinib can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Dasatinib can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Adenosine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Dasatinib.]
[C03DA04, eplerenone, The metabolism of Dasatinib can be decreased when combined with Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Melperone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Dasatinib.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Dasatinib.]
[J01FA03, midecamycin, The metabolism of Dasatinib can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Dasatinib can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Dasatinib can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, Dasatinib may increase the immunosuppressive activities of Cyclosporine.]
[N06BA07, modafinil, The metabolism of Dasatinib can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Dasatinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dasatinib.]
[C10AA07, rosuvastatin, The metabolism of Dasatinib can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Dasatinib can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Dasatinib.]
[J05AF10, entecavir, The metabolism of Dasatinib can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Dasatinib.]
[M01AH05, etoricoxib, The metabolism of Dasatinib can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dasatinib.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dasatinib.]
[G03XA01, danazol, The metabolism of Dasatinib can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dasatinib can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The metabolism of Dasatinib can be decreased when combined with Daunorubicin.]
[M01AX01, nabumetone, The metabolism of Dasatinib can be decreased when combined with Nabumetone.]
[N06AX06, nefazodone, The metabolism of Dasatinib can be decreased when combined with Nefazodone.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Dasatinib.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fondaparinux.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dasatinib.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Solifenacin.]
[N06AA01, desipramine, The metabolism of Dasatinib can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Dasatinib.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dasatinib.]
[N03AF02, oxcarbazepine, The metabolism of Dasatinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dasatinib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Dasatinib can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dasatinib can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Dasatinib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Dasatinib can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The metabolism of Dasatinib can be decreased when combined with Dextromethorphan.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Dasatinib.]
[N06AB05, paroxetine, The metabolism of Dasatinib can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, Dasatinib may increase the anticoagulant activities of Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Dasatinib.]
[N05BA01, diazepam, The metabolism of Dasatinib can be decreased when combined with Diazepam.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Dasatinib can be decreased when combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Dasatinib can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dasatinib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Pinaverium.]
[L01DC04, ixabepilone, The serum concentration of Dasatinib can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Dasatinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, The metabolism of Dasatinib can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Dasatinib can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Dasatinib can be increased when combined with Difluocortolone.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Dasatinib.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Dasatinib.]
[C02DB01, dihydralazine, The metabolism of Dasatinib can be decreased when combined with Dihydralazine.]
[C10AX09, ezetimibe, Dasatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dasatinib.]
[C04AE04, dihydroergocristine, The metabolism of Dasatinib can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Dasatinib.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dasatinib.]
[J05AE08, atazanavir, The metabolism of Dasatinib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dasatinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Dasatinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Dasatinib can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Dasatinib can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Dasatinib.]
[C05CA03, diosmin, The serum concentration of Dasatinib can be increased when it is combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Dasatinib.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The metabolism of Dasatinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Dasatinib.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.]
[P03AA04, disulfiram, The metabolism of Dasatinib can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The serum concentration of Dasatinib can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dasatinib can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Dasatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The metabolism of Dasatinib can be decreased when combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levocetirizine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Dasatinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The metabolism of Dasatinib can be decreased when combined with Rosoxacin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Dasatinib.]
[A04AD12, aprepitant, The metabolism of Dasatinib can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Dasatinib.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Dasatinib.]
[J05AE07, fosamprenavir, The metabolism of Dasatinib can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The metabolism of Dasatinib can be decreased when combined with Tadalafil.]
[C02KX02, ambrisentan, The metabolism of Dasatinib can be decreased when combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Dasatinib can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Dasatinib can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Dasatinib.]
[A03FA03, domperidone, The metabolism of Dasatinib can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dasatinib can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Doxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Dasatinib.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Dasatinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Dasatinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Droperidol.]
[C10AA01, simvastatin, The serum concentration of Dasatinib can be increased when it is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sultopride.]
[N02CC01, sumatriptan, Dasatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Talinolol.]
[H01AA01, corticotropin, The metabolism of Dasatinib can be increased when combined with Corticotropin.]
[J01MA05, temafloxacin, The metabolism of Dasatinib can be decreased when combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Dasatinib.]
[D01BA02, terbinafine, The metabolism of Dasatinib can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Terodiline.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Dasatinib.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Dasatinib.]
[N03AX11, topiramate, The metabolism of Dasatinib can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Dasatinib can be increased when it is combined with Toremifene.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Dasatinib.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Dasatinib.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Triptorelin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Dasatinib is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Troxerutin.]
[J01MA04, enoxacin, The metabolism of Dasatinib can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Dasatinib.]
[S01GX10, epinastine, Epinastine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Dasatinib which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Dasatinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Dasatinib can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Dasatinib.]
[N05CF02, zolpidem, The metabolism of Dasatinib can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The serum concentration of Dasatinib can be increased when it is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Dasatinib.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Dasatinib.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Dasatinib.]
[B01AC11, iloprost, Dasatinib may increase the anticoagulant activities of Iloprost.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Dasatinib.]
[N02CA02, ergotamine, The metabolism of Dasatinib can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The metabolism of Dasatinib can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The serum concentration of Dasatinib can be increased when it is combined with Erythromycin.]
[A02BC02, pantoprazole, Pantoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H05BX01, cinacalcet, The metabolism of Dasatinib can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Dasatinib can be decreased when combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Dasatinib.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Dasatinib can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Dasatinib can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The metabolism of Dasatinib can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Dasatinib can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Dasatinib can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Dasatinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Dasatinib.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Dasatinib.]
[R06AX12, terfenadine, The metabolism of Dasatinib can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Dasatinib can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Dasatinib can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Dasatinib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Dasatinib.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dextran.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dasatinib.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P02CA03, albendazole, The metabolism of Dasatinib can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Dasatinib can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Dasatinib can be decreased when combined with Fenfluramine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Dasatinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dasatinib.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Dasatinib.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Dasatinib.]
[C01BC04, flecainide, The metabolism of Dasatinib can be decreased when combined with Flecainide.]
[J01CF05, floxacillin, The metabolism of Dasatinib can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Dasatinib can be increased when it is combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Dasatinib.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dasatinib.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Dasatinib.]
[D07AC08, fluocinonide, The metabolism of Dasatinib can be increased when combined with Fluocinonide.]
[H02AB03, fluocortolone, The metabolism of Dasatinib can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Dasatinib can be increased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Dasatinib.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dasatinib.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dasatinib.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Dasatinib.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dasatinib.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Dasatinib can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Dasatinib may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Dasatinib.]
[J05AE10, darunavir, The serum concentration of Dasatinib can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Dasatinib.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dasatinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Dasatinib can be increased when combined with Barbexaclone.]
[C10AB04, gemfibrozil, The metabolism of Dasatinib can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Degarelix.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, The metabolism of Dasatinib can be decreased when combined with Pipemidic acid.]
[M01AG01, mefenamic acid, The metabolism of Dasatinib can be decreased when combined with Mefenamic acid.]
[R03BA09, fluticasone furoate, The metabolism of Dasatinib can be increased when combined with Fluticasone furoate.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Dasatinib.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Dasatinib.]
[J05AG04, etravirine, The metabolism of Dasatinib can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methsuximide.]
[N01AH02, alfentanil, The metabolism of Dasatinib can be decreased when combined with Alfentanil.]
[L01EH01, lapatinib, The serum concentration of Dasatinib can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Dasatinib can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The metabolism of Dasatinib can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Dasatinib.]
[C02CA04, doxazosin, The metabolism of Dasatinib can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Dasatinib.]
[L01EX02, sorafenib, The serum concentration of Dasatinib can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Dasatinib.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fluindione.]
[D01BA01, griseofulvin, The metabolism of Dasatinib can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Dasatinib can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Histrelin.]
[N05AH04, quetiapine, The metabolism of Dasatinib can be decreased when combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Dasatinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Dasatinib.]
[C09CA01, losartan, The metabolism of Dasatinib can be decreased when combined with Losartan.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Dasatinib can be decreased when combined with Allylestrenol.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Dasatinib.]
[J05AG01, nevirapine, The metabolism of Dasatinib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Dasatinib can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Dasatinib may increase the anticoagulant activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Oxatomide.]
[C02DB02, hydralazine, The metabolism of Dasatinib can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dasatinib.]
[S02BA01, hydrocortisone, The metabolism of Dasatinib can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Dasatinib.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Dasatinib is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Dasatinib.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Dasatinib can be increased when combined with Rifabutin.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Dasatinib.]
[L01AA06, ifosfamide, The metabolism of Dasatinib can be increased when combined with Ifosfamide.]
[H01AC02, somatrem, The metabolism of Dasatinib can be increased when combined with Somatrem.]
[N06AA02, imipramine, The metabolism of Dasatinib can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Dasatinib can be increased when combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Dasatinib is combined with Tixocortol.]
[M03BX02, tizanidine, The metabolism of Dasatinib can be decreased when combined with Tizanidine.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Dasatinib.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dasatinib.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dasatinib.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dasatinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dasatinib.]
[N06AX17, milnacipran, The metabolism of Dasatinib can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Dasatinib can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Dasatinib.]
[N05CH02, ramelteon, The metabolism of Dasatinib can be decreased when combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dasatinib.]
[C10AA06, cerivastatin, The metabolism of Dasatinib can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, Dasatinib may increase the anticoagulant activities of Anagrelide.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dasatinib.]
[J05AB13, penciclovir, The metabolism of Dasatinib can be decreased when combined with Penciclovir.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Dasatinib.]
[J04AC01, isoniazid, The metabolism of Dasatinib can be decreased when combined with Isoniazid.]
[P02CF01, ivermectin, Dasatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bivalirudin.]
[H01AC01, somatropin, The metabolism of Dasatinib can be increased when combined with Somatotropin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Dasatinib can be increased when combined with Tocilizumab.]
[C02KD01, ketanserin, Dasatinib may increase the anticoagulant activities of Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Dasatinib can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AC03, deferasirox, The serum concentration of Dasatinib can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Dasatinib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mizolastine.]
[J01MB02, nalidixic acid, The metabolism of Dasatinib can be decreased when combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dasatinib.]
[N03AX18, lacosamide, The metabolism of Dasatinib can be decreased when combined with Lacosamide.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Dasatinib.]
[G03AD01, levonorgestrel, The metabolism of Dasatinib can be decreased when combined with Levonorgestrel.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Dasatinib can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Dasatinib.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Dasatinib.]
[A07DA03, loperamide, The serum concentration of Dasatinib can be increased when it is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Dasatinib.]
[N05AH01, loxapine, The serum concentration of Dasatinib can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Dasatinib can be increased when it is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Dasatinib is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Dasatinib can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Dasatinib can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dasatinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dasatinib.]
[P01BC02, mefloquine, The serum concentration of Dasatinib can be increased when it is combined with Mefloquine.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dalteparin.]
[N05CH01, melatonin, The metabolism of Dasatinib can be decreased when combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Dasatinib.]
[N02AB02, meperidine, The metabolism of Dasatinib can be decreased when combined with Meperidine.]
[N03AB04, mephenytoin, The metabolism of Dasatinib can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Dasatinib can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The metabolism of Dasatinib can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mesoridazine.]
[N05AX13, paliperidone, The serum concentration of Dasatinib can be increased when it is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Dasatinib can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Dasatinib can be decreased when combined with Methadone.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF05, lamivudine, Dasatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[H03BB02, methimazole, The metabolism of Dasatinib can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dasatinib.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Dasatinib.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Dasatinib can be decreased when combined with Methoxsalen.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Dasatinib.]
[V04CG05, methylene blue, The serum concentration of Dasatinib can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Dasatinib can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Dasatinib.]
[H02AB04, methylprednisolone, The metabolism of Dasatinib can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The metabolism of Dasatinib can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Dasatinib can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dasatinib.]
[P01AB01, metronidazole, The metabolism of Dasatinib can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Dasatinib can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Dasatinib can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Dasatinib.]
[S02AA13, miconazole, The metabolism of Dasatinib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Dasatinib.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Dasatinib.]
[G03XB01, mifepristone, The serum concentration of Dasatinib can be decreased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Tinzaparin.]
[J01FA11, miocamycin, The metabolism of Dasatinib can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Dasatinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Dasatinib.]
[L03AC01, aldesleukin, The metabolism of Dasatinib can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Dasatinib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Dasatinib can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Dasatinib can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Dasatinib can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Dasatinib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dasatinib.]
[N05CA02, amobarbital, The metabolism of Dasatinib can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dasatinib.]
[G04CA04, silodosin, The serum concentration of Dasatinib can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Dasatinib can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Dasatinib.]
[N03AB05, fosphenytoin, The metabolism of Dasatinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dasatinib.]
[J01CF06, nafcillin, The metabolism of Dasatinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Dasatinib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Dasatinib can be increased when combined with Anakinra.]
[M02AA12, naproxen, The metabolism of Dasatinib can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Dasatinib can be increased when combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dasatinib.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Dasatinib.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levosimendan.]
[B01AC17, tirofiban, Dasatinib may increase the anticoagulant activities of Tirofiban.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Dasatinib.]
[N06AX23, desvenlafaxine, The metabolism of Dasatinib can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Dasatinib which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Dasatinib can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Dasatinib.]
[C10AD02, niacin, The metabolism of Dasatinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Dasatinib can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Dasatinib can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Dasatinib can be decreased when combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Nimodipine.]
[C08CA07, nisoldipine, The metabolism of Dasatinib can be decreased when combined with Nisoldipine.]
[C08CA08, nitrendipine, The metabolism of Dasatinib can be decreased when combined with Nitrendipine.]
[J01XE01, nitrofurantoin, Dasatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Dasatinib can be decreased when combined with Zaleplon.]
[G03DC02, norethindrone, The metabolism of Dasatinib can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The metabolism of Dasatinib can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, The metabolism of Dasatinib can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Dasatinib.]
[R05DA07, noscapine, The metabolism of Dasatinib can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Dasatinib can be increased when it is combined with Sapropterin.]
[B01AC16, eptifibatide, Dasatinib may increase the anticoagulant activities of Eptifibatide.]
[L03AB07, interferon beta-1a, The metabolism of Dasatinib can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of Dasatinib can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Dasatinib can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Dasatinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Ancrod.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Oxolinic acid.]
[N02AA05, oxycodone, The metabolism of Dasatinib can be decreased when combined with Oxycodone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dasatinib.]
[N05AH05, asenapine, Asenapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Danaparoid.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Papaverine.]
[H02AB05, paramethasone, The metabolism of Dasatinib can be increased when combined with Paramethasone.]
[J01MA03, pefloxacin, The metabolism of Dasatinib can be decreased when combined with Pefloxacin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Dasatinib.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dasatinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dasatinib.]
[N05CA01, pentobarbital, The metabolism of Dasatinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Dasatinib.]
[C04AD03, pentoxifylline, Dasatinib may increase the anticoagulant activities of Pentoxifylline.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Dasatinib.]
[N05AB03, perphenazine, The metabolism of Dasatinib can be decreased when combined with Perphenazine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dasatinib.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Dasatinib.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Dasatinib can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Phenprocoumon.]
[M02AA01, phenylbutazone, The metabolism of Dasatinib can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Dasatinib can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB02, phenytoin, The metabolism of Dasatinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dasatinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Dasatinib can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The serum concentration of Dasatinib can be increased when it is combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Dasatinib.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Dasatinib.]
[J05AE01, saquinavir, The metabolism of Dasatinib can be decreased when combined with Saquinavir.]
[J01MA11, grepafloxacin, The metabolism of Dasatinib can be decreased when combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Dasatinib can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Dasatinib can be decreased when combined with Irbesartan.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Alteplase.]
[A03AE01, alosetron, The metabolism of Dasatinib can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Dasatinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Dasatinib.]
[J05AE03, ritonavir, The metabolism of Dasatinib can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Dasatinib can be decreased when combined with Saxagliptin.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Dasatinib.]
[C10AA08, pitavastatin, Dasatinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prajmaline.]
[P02BA01, praziquantel, The metabolism of Dasatinib can be decreased when combined with Praziquantel.]
[C02CA01, prazosin, Dasatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The metabolism of Dasatinib can be increased when combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Dasatinib.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Dasatinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dasatinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Dasatinib can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Dasatinib.]
[C10AB05, fenofibrate, The metabolism of Dasatinib can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Dasatinib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Dasatinib can be decreased when combined with Promazine.]
[R06AD02, promethazine, Promethazine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01BC03, propafenone, The serum concentration of Dasatinib can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Dasatinib can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Dasatinib.]
[N01AX10, propofol, The metabolism of Dasatinib can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dasatinib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Dasatinib can be decreased when combined with Propranolol.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Dasatinib.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Dasatinib.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Dasatinib.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dasatinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Mepyramine.]
[P01AX05, quinacrine, The metabolism of Dasatinib can be decreased when combined with Quinacrine.]
[C01BA01, quinidine, The serum concentration of Dasatinib can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Dasatinib can be increased when it is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02AA02, reserpine, The serum concentration of Dasatinib can be increased when it is combined with Reserpine.]
[J04AB02, rifampin, The serum concentration of Dasatinib can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Dasatinib can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dasatinib.]
[N05CA06, secobarbital, The metabolism of Dasatinib can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Dasatinib can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Dasatinib is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.]
[H01CB01, somatostatin, The metabolism of Dasatinib can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Dasatinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.]
[D07AB02, hydrocortisone butyrate, The metabolism of Dasatinib can be increased when combined with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The metabolism of Dasatinib can be decreased when combined with Levoketoconazole.]
